Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor

Laboratory Investigation

Volumn 78, Issue 9, 1998, Pages 1109-1119

  Fibbi, Gabriella ^a   Caldini, Riccardo ^a   Chevanne, Marta ^a   Pucci, Marco ^a   Schiavone, Nicola ^a   Morbidelli, Lucia ^b   Parenti, Astrid ^b   Granger, Harris J ^c   Rosso, Mario Del ^a   Ziche, Marina ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Dipto Farmacol Preclinica e Clin   (Italy)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR 2; PROTEIN KINASE C; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CORNEA; ENDOTHELIUM CELL; GLUCOSE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; CORNEA; DIGLYCERIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GLUCOSE TRANSPORTER TYPE 2; HUMANS; LAMININ; MONOSACCHARIDE TRANSPORT PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEOGLYCANS; RABBITS; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031684740     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Andreasen PA, Kjoller L, Christensen L, and Duffy MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72:1-22.
2. Anichini E, Fibbi G, Pucci M, Caldini R, Chevanne M, and Del Rosso M (1994). Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp Cell Res 213:438-448.
3. Berman M, Winthrop S, Ausprunk D, Rose J, Langer R, and Gage J (1982). Plasminogen activation (urokinase) causes vascularization of the cornea. Invest Opthalmol Vis Sci 22: 191-199.
4. Bloch R (1983). Inhibition of glucose transport in the human erythrocyte by cytochalasin B. Biochemistry 12:4899-4901.
5. Bohuslav BJ, Horejsμ V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, and Stockinger H (1995). Urokinase plasminogen activator receptor, β2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 181:1381-1390.
6. Bouck N, Stellmach V, and Hsu SC (1996). How tumors become angiogenic. Adv Cancer Res 69:135-174.
7. Busso N, Masur SK, Lazega D, Waxman S, and Ossowski L (1994). Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanisms for signal transduction in human epithelial cells. J Cell Biol 126:259-270.
8. De Petro G, Copeta A, and Barlati S (1994). Urokinase-type and tissue type plasminogen activators as growth factors in human fibroblasts. Exp Cell Res 213:286-294.
9. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, and Ruggiero M (1993). Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun 190:347-352.
10. Del Rosso M, Pedersen N, Fibbi G, Pucci M, Dini G, Anichini E, and Blasi F (1992). Selective localization of receptors for urokinase amino-terminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells. Exp Cell Res 203:427-434.
11. Dumler I, Petri T, and Schleuning W-D (1994). Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation of a 38 kDa protein. FEBS Lett 322:37-40.
12. Fibbi G, Magnelli L, Pucci M, and Del Rosso M (1990). Interaction of urokinase with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator. Exp Cell Res 187:33-38.
13. Fibbi G, Ziche M, Morbidelli L, Magnelli L, and Del Rosso M (1988). Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 179:385-395.
14. Gimbrone MA, Cotran RS, and Folkman J (1974). Human vascular endothelial cells in culture. J Cell Biol 60:673-684.
15. Goldfarb RH, Ziche M, Murano G, and Liotta LA (1986). Plasminogen activators (urokinase) mediate neovascularization: Possible role in tumor angiogenesis. Semin Thromb Hemost 12:337-338.
16. Kook YH, Adamski J, Zelent A, and Ossowski L (1994). The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13:3983-3991.
17. Lacal JC, Moscat J, and Aaronson SA (1987). Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha.ras oncogene. Nature 330:269-272.
18. Lee TS, MacGregor LC, Fluharty SJ, and King GL (1989). Differential regulation of protein kinase C and (Na, k)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 93:90-94.
19. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, and Vassalli JD (1993). Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122: 673-684.
20. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, and Del Rosso M (1995). Reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55:90-95.
21. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, and Fazioli F (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572-1562.
22. Schelling ME, Meininger CJ, Hawker JR, and Granger HJ (1988). Venular endothelial cells from bovine heart. Am J Physiol 254:1211-1217.
23. Vassalli J-D and Pepper M. Membrane proteases in focus. Nature (1994). 370:14.
24. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G, and Persico GM (1997a). Placenta growth factor-1 (PIGF-1) is chemotactic, mitogenic and angiogenic. Lab Invest 76:517-531.
25. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, and Ledda F (1994). Nitric oxide mediates angionenesis in vivo and endothelial cell growth and migration promoted by substance P. J Clin Invest 94:2036-2044.
26. Ziche M, Parenti A, Ledda F, Dell' Era P, Granger HJ, Maggi CA, and Presta M (1997b). Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 80:845-852.